The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients

• Published in: Scientific reports Vol. 10; no. 1; p. 12811
• Main Authors: Kinjo, Takumi, Kitaguchi, Yoshiaki, Droma, Yunden, Yasuo, Masanori, Wada, Yosuke, Ueno, Fumika, Ota, Masao, Hanaoka, Masayuki
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 30.07.2020; Nature Publishing Group UK
• Subjects: Advanced glycosylation end products; Aged; Alleles; Asian Continental Ancestry Group; Chronic obstructive pulmonary disease; Emphysema; Emphysema - genetics; Enzyme-linked immunosorbent assay; Female; Fibrosis; Gene frequency; Genotyping; Glycosylation; Humans; Lung diseases; Male; Middle Aged; Mutation; Obstructive lung disease; Pathogenesis; Polymorphism, Single Nucleotide; Pulmonary Disease, Chronic Obstructive - genetics; Pulmonary Emphysema - genetics; Pulmonary fibrosis; Pulmonary Fibrosis - genetics; Receptor for Advanced Glycation End Products - genetics; Receptor for Advanced Glycation End Products - metabolism; Serum levels; Single-nucleotide polymorphism
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-69184-8

The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidate the pathogenesis of CPFE, we genotyped three single nucleotide polymorphisms (SNPs: rs2070600, rs1800625, and rs2853807) of the gene encoding RAGE (AGER) in 111 CPFE patients and 337 chronic obstructive pulmonary disease (COPD) patients of Japanese by using StepOne Real-Time PCR System for SNP genotyping assay. Serum levels of soluble RAGE (sRAGE) were measured by ELISA. We found that the allele frequency of rs2070600 was significantly different between the two groups [corrected P (Pc) = 0.015]. In addition, the minor allele was associated with CPFE patients relative to COPD patients in a dominant effect model (Odds Ratio = 1.93; Pc = 0.018). Moreover, the serum sRAGE level was significantly lower in the CPFE group than the COPD group (P = 0.014). The rs2070600 minor allele was significantly associated with reduced sRAGE level in CPFE patients and independently affected sRAGE level reduction in this group (P = 0.020). We concluded that the AGER rs2070600 minor allele (Gly82Ser mutation) is associated with the pathogenesis of pulmonary fibrosis in CPFE in Japanese patients.